Biocartis – Idylla for Colorectal Cancer
Biocartis Idylla™ for colorectal cancer
The Idylla solution is a revolutionary, fully automated, real-time PCR based molecular testing system designed to offer results in a minimum amount of time.
19Mar
News
27Feb
Histocyte BRAF Analyte Control IHC
BRAF analyte control from HistoCyte, two cell lines of positive & negative BRAF V600E expression.
20Nov
HistoCyte – Lung Cancer controls
Gaining over 15,000 cases this 2024 and leading with the lowest survival rate for cancer types, lung cancer has been in the forefront of cancer cases in Australia. Biomarkers such ALK, ROS1, PD-L1, and BRAF are used in IHC and molecular laboratory techniques to identify specific types of lung cancer and guide targeted therapy.
08Oct
Think Biocartis Idylla
WHEN TIME MATTERS. THINK BIOCARTIS IDYLLA*. YOUR BIOMARKER TEST RESULTS WITHIN 3 HOURS.
The Idylla™ solution is a revolutionary, fully automated, real-time PCR based molecular testing system designed to offer results in a minimum amount of time.
24Mar
New Study Shows Rapid EGFR testing with Idylla!
Products are for professional/laboratory use only.
Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes
03Feb
Study Reviewing 2,500 Performed Idylla Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods
Products are for professional/laboratory use only.
Press Release: Mechelen, Belgium, 27 June 2018
02Feb
Idylla platform – real-time PCR-based molecular diagnostics system
Products are for professional/laboratory use only.
Idylla™, Biocartis’ fully automated, real-time PCR based molecular diagnostics system, is designed to offer fast and easy access to clinical molecular diagnostic information, anywhere and anytime.
21May
Biocartis Idylla BRAF Mutation Test
Introducing Biocartis Idylla – BRAF molecular results in as little as 90 minutes.
About 50 percent of all melanomas harbor mutations in the BRAF oncogene. Idylla™ BRAF Mutation Test detects BRAF mutations directly from FFPE tissue sections in 90 minutes with less than 2 minutes hands-on time.